Cytek Biosciences Q1 2024 Adj EPS $(0.05) Misses $(0.04) Estimate, Sales $44.900M Beat $43.586M Estimate

5/8/24 4:08:59 PM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $CTKB alert in real time by email

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $44.900 million which beat the analyst consensus estimate of $43.586 million by 3.01 percent. This is a 21.06 percent increase over sales of $37.088 million the same period last year.

Get the next $CTKB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTKB

Date	Price Target	Rating	Analyst
12/14/2023	$9.00	Overweight	Stephens
7/19/2023		Mkt Perform	Raymond James
2/15/2022	$27.00 → $18.00	Equal-Weight	Morgan Stanley
1/6/2022	$20.00	Overweight	Piper Sandler
10/15/2021		Outperform	Cowen
8/17/2021		Outperform	Cowen
8/17/2021		Equal-Weight	Morgan Stanley
8/17/2021	$26.00	Equal-Weight	Morgan Stanley

More analyst ratings

$CTKB
Press Releases

Fastest customizable press release news feed in the world

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference
FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference in New York, NY. Cytek management is scheduled to participate in a fireside chat on Tuesday, December 3, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next gen
11/20/24 4:05:00 PM ET
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system. This is the first commercially available small particle detector on a cell sorter and offers a significant advancement for rapidly evolving research fields, including in drug delivery, cell therapy, disease diagnostics, circulating tumor cells, regenerative medicine, and vaccine delivery. Researchers can now achieve downstream analysis of materials that were previously unable to be sorted, opening new possibilities for breakthroughs in these areas. Once regarded as cellular debris, exosomes and extracell
11/7/24 5:00:00 PM ET
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials
Cytek Biosciences Reports Third Quarter 2024 Financial Results
FREMONT, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Total revenue for the third quarter of 2024 was $51.5 million, representing a 7% increase over the third quarter of 2023 and a 10% increase over the second quarter of 2024. Year-to-date revenue of $143.0 million at September 30, 2024 was 6% above the same 9 month period in 2023 Launched SpectroPanel™ tool, a proprietary new intelligent algorithm which suggests optimized panels in minutes, expanding the capabilities of the Pane
11/5/24 4:05:00 PM ET
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials

$CTKB
Financials

Live finance-specific insights

Cytek Biosciences Reports Third Quarter 2024 Financial Results
FREMONT, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Total revenue for the third quarter of 2024 was $51.5 million, representing a 7% increase over the third quarter of 2023 and a 10% increase over the second quarter of 2024. Year-to-date revenue of $143.0 million at September 30, 2024 was 6% above the same 9 month period in 2023 Launched SpectroPanel™ tool, a proprietary new intelligent algorithm which suggests optimized panels in minutes, expanding the capabilities of the Pane
11/5/24 4:05:00 PM ET
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials
Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024
FREMONT, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 5, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the nex
10/29/24 4:05:00 PM ET
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials
Cytek Biosciences Reports Second Quarter 2024 Financial Results
FREMONT, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Total revenue for the second quarter of 2024 was $46.6 million, representing a 4% increase sequentially over the first quarter of 2024 and a 6% decrease over the second quarter of 2023For the first half of 2024, total revenue grew 5% compared to the first half of 2023Launched Enhanced Small Particle (ESP™) detection, an upgrade option for the Cytek Aurora™ and Northern Lights™ systems for the analysis of viruses and other sub-
8/6/24 4:05:00 PM ET
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials

$CTKB
Leadership Updates

Live Leadership Updates

Cytek Announces Resignation of Chief Operating Officer Chris Williams
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef
9/12/24 3:20:00 PM ET
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials
Cytek® Biosciences Names William McCombe Chief Financial Officer
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-
3/19/24 8:00:00 AM ET
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services
FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services. In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and technical application support, building on the recently integrated sales team that combines the original Cytek sales force with the Amnis® and Guava® sales force. "Philippe's extensive global sales and marketing experience as an executive at several life science companies, incl
8/28/23 5:30:00 AM ET
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials

Cytek Biosciences Q1 2024 Adj EPS $(0.05) Misses $(0.04) Estimate, Sales $44.900M Beat $43.586M Estimate

Chat with this insight

Recent Analyst Ratings for $CTKB

$CTKB Press Releases

Fastest customizable press release news feed in the world

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

Cytek Biosciences Reports Third Quarter 2024 Financial Results

$CTKB Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Cytek Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

SEC Form SC 13G filed by Cytek Biosciences Inc.

$CTKB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$CTKB SEC Filings

$CTKB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SVP, GLOBAL SALES AND SERVICES Busque Philippe converted options into 3,746 shares and covered exercise/tax liability with 1,460 shares, increasing direct ownership by 22% to 12,871 units (SEC Form 4)

CHIEF LEGAL OFFICER Barnett Valerie converted options into 13,432 shares and covered exercise/tax liability with 4,499 shares, increasing direct ownership by 17% to 62,850 units (SEC Form 4)

PRESIDENT AND CEO Jiang Wenbin covered exercise/tax liability with 9,897 shares and converted options into 40,639 shares, increasing direct ownership by 0.60% to 5,187,638 units (SEC Form 4)

Cytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

SEC Form 8-K filed by Cytek Biosciences Inc.

SEC Form 10-Q filed by Cytek Biosciences Inc.

Stephens initiated coverage on Cytek Biosciences with a new price target

Raymond James initiated coverage on Cytek Biosciences

Morgan Stanley reiterated coverage on Cytek Biosciences with a new price target

$CTKB Financials

Live finance-specific insights

Cytek Biosciences Reports Third Quarter 2024 Financial Results

Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

Cytek Biosciences Reports Second Quarter 2024 Financial Results

$CTKB Market Insights

Live Market Insights

Cytek Biosciences Announces $50M Stock Repurchase Program

Cytek Biosciences Says Its 1-laser And 2-laser 6-color TBNK Reagent Cocktails Have Received China NMPA Approval For Clinical Diagnostic Use

Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8.5

$CTKB Leadership Updates

Live Leadership Updates

Cytek Announces Resignation of Chief Operating Officer Chris Williams

Cytek® Biosciences Names William McCombe Chief Financial Officer

Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services

Recent Analyst Ratings for
$CTKB

$CTKB
Press Releases

$CTKB
Large Ownership Changes

$CTKB
Insider Trading

$CTKB
SEC Filings

$CTKB
Analyst Ratings

$CTKB
Financials

$CTKB
Market Insights

$CTKB
Leadership Updates